Neurite

Souvenaid Launches a New Memory Supplement with a Unique Nutritional Approach to Help Strengthen Synapses

Retrieved on: 
Monday, April 17, 2023
Medicine, Bureau of Oceans and International Environmental and Scientific Affairs, Food allergy, Stroke, SCD, Penile spines, Ageing, Cancer, Nutrient, Phospholipid, Brain, Dementia, Cognitive science, Calcium, CDC, Vitamin, Membrane, Uridine, Protein, MD, DSM-IV codes, Amazon (company), MIT Department of Brain and Cognitive Sciences, Synapse, Amnesia, Confusion, Knowledge, Vitamin D, Massachusetts Institute of Technology, Choline, Memory, Conditional sentence, Neurite, Dietary supplement, RD, Doctor of Philosophy, Americans

ROCKVILLE, Md., April 17, 2023 /PRNewswire/ -- Souvenaid, the first and only memory supplement specifically designed to support memory function through a specialized blend of nutrients that help strengthen synapses, was introduced to the U.S. market today by Nutricia.  During normal aging, memory decline is linked to changes in the brain and the functioning of synapses – the brain connections that make it possible to create and recall memories.  One daily four-ounce serving of Souvenaid powers synapses with the right nutrients at the right levels, using its proprietary formula Fortasyn Connect™, which cannot be found in any other memory supplement. Fortasyn Connect is a well-researched blend of key nutrients that are understood to help support synapses in the brain. This combination and concentration of each nutrient is nearly impossible to get from typical diet alone.

Key Points: 
  • Fortasyn Connect is a well-researched blend of key nutrients that are understood to help support synapses in the brain.
  • Souvenaid, the first and only memory supplement specifically designed to support memory function through a specialized blend of nutrients that help strengthen synapses, was introduced to the U.S. market today by Nutricia.
  • Just like calcium strengthens our bones, the nutrients that make up Fortasyn Connect help strengthen how synapses function.
  • Souvenaid was developed based on the knowledge that these are the prerequisites to support new synapses and strengthen existing ones.

Fresh Bros: New Wild Lettuce Research Shows Promise as a Nootropic and Painkiller

Retrieved on: 
Monday, October 25, 2021
Sleep, Research, Arthritis, Asteraceae, Neurite, Journal of Ethnopharmacology, Inflammation, Plant, Pain, GLOBE, Central nervous system, Journal, Vegetable

Wild lettuce is just one such plant that has been used this way, usually for pain relief and to aid sleep.

Key Points: 
  • Wild lettuce is just one such plant that has been used this way, usually for pain relief and to aid sleep.
  • Wild lettuce (lactuca virosa) has recently shown promise in research as both a nootropic (a substance that can help improve cognitive function) and painkiller.
  • Wild lettuce contains two beneficial compounds (lactucin and lactucopicrin) that act on the central nervous system as a painkiller and sedative.
  • Based on these properties, it is thought that wild lettuce may be able to help prevent or alleviate certain conditions including:

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting

Retrieved on: 
Thursday, October 7, 2021
Forward-looking statement, Lists of diseases, Brain, FTLD, Stealth, PSP, Amyotrophic lateral sclerosis, Degenerative disease, Leber's hereditary optic neuropathy, Neurodegeneration, Friedreich's ataxia, Traffic barrier, COVID-19, Heart, Marketing, Duchenne muscular dystrophy, Neuron, Safety, Annual report, ALS, Alzheimer's disease, U.S. Securities and Exchange Commission, IgG4-related ophthalmic disease, Frontotemporal lobar degeneration, Private Securities Litigation Reform Act, LBD, Pathology, Neurite, Hope, Elamipretide, TAR, Mitochondrial disease, Barth syndrome, DNA, Eye, Patient, Risk, Nasdaq, Parkinson's disease, Pharmaceutical industry

The data were presented at the virtual 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting held October 6-7, 2021.

Key Points: 
  • The data were presented at the virtual 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting held October 6-7, 2021.
  • This preclinical study evaluated the effects of SBT-272 on mitochondrial function, morphology, and motility in mouse corticospinal motor neurons with mutant TDP-43 pathology.
  • We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data.
  • Such forward-looking statements include, but are not limited to, those regardingthe implications of preliminary preclinical data.